Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
There were no significant changes in the vitamin D values from baseline (Q2, 2024) to follow-up (Q3, 2024), either in the verum (41 ng/ml ± 21 to 44 ng/ml ± 21) or in the placebo group (41 ng/ml ± 28 to 40 ng/ml ± 28).
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Randomised controlled trial.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Propionic acid in multiple sclerosis: a phase 2b, double-blind, randomized placebo-controlled trial
Source: Article title.
Propionic acid in multiple sclerosis: a phase 2b, double-blind, randomized placebo-controlled trial
Source: Article title.
Recruitment began in Q1 2024, and participants were enrolled by Q2 2024.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Propionic acid in multiple sclerosis: a phase 2b, double-blind, randomized placebo-controlled trial
Randomised controlled trial · Brain · 2026
Original publication title
Propionic acid in multiple sclerosis: a phase 2b, double-blind, randomized placebo-controlled trial
© The Author(s) 2026. Published by Oxford University Press on behalf of the Guarantors of Brain.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Abstract
Propionic acid (PA), a microbial-derived short-chain fatty acid, contributes to intestinal barrier integrity, systemic immune regulation, and neuronal function. Individuals with multiple sclerosis show reduced PA levels, and open-label data have suggested beneficial immunomodulatory and clinical effects of supplementation.
The Multiple sclerosis And DisAbility Improvement (MADAI) trial was a randomized, double-blind, placebo-controlled, single-centre, phase 2b study designed to evaluate the efficacy and safety of PA as an add-on therapy in adults with clinically stable multiple sclerosis. Between April 5 and 29 May 2024, 101 adults (64% women; mean age 45 years) were randomly assigned in a 2:1 ratio to receive PA 500 mg twice daily or matching placebo for 90 days. The primary outcome was the change in serum neurofilament light chain (sNfL) concentration, a biomarker of neuroaxonal damage, adjusted for age, body mass index, creatinine, and baseline sNfL.
Secondary outcomes included physical and cognitive performance measures and patient-reported outcomes, including fatigue and quality of life scores.
sNfL levels were significantly reduced in the PA group {−17.9%; from 9.77 pg/ml [95% confidence interval (CI) 9.00 to 10.60] to 8.02 pg/ml (95% CI 7.36 to 8.73); mean difference 1.75 pg/ml (95% CI 0.9 to 2.6); P = 0.000025}, while no significant change was observed in the placebo group. The adjusted mean difference in sNfL levels between the PA and placebo groups at follow-up was 0.91 pg/ml (95% CI 0.02 to 1.79; P = 0.045). Reductions in sNfL were also observed among participants in the PA arm receiving moderate-to-high efficacy disease-modifying therapies (n = 41; P = 0.0001), including those on anti-CD20 treatment (n = 27; P = 0.0005).
There was a trend towards improvement in motor fatigue in the PA group. No serious adverse events related to the study medication occurred.
PA supplementation was well tolerated and associated with significant reductions in sNfL, suggesting attenuation of neuroaxonal injury in multiple sclerosis. These findings support further evaluation of PA as an add-on treatment in larger, long-term studies.
Moser et al. evaluated the efficacy and safety of propionic acid (PA) as an add-on therapy in adults with clinically stable multiple sclerosis. They found that PA supplementation was well-tolerated and was associated with significant reductions in serum neurofilament light chain levels and a trend toward improvement in fatigue.
See Sandgren et al. (https://doi.org/10.1093/brain/awag192) for a scientific commentary on this article.
Authors’ abstract
Abstract
Propionic acid (PA), a microbial-derived short-chain fatty acid, contributes to intestinal barrier integrity, systemic immune regulation, and neuronal function. Individuals with multiple sclerosis show reduced PA levels, and open-label data have suggested beneficial immunomodulatory and clinical effects of supplementation.
The Multiple sclerosis And DisAbility Improvement (MADAI) trial was a randomized, double-blind, placebo-controlled, single-centre, phase 2b study designed to evaluate the efficacy and safety of PA as an add-on therapy in adults with clinically stable multiple sclerosis. Between April 5 and 29 May 2024, 101 adults (64% women; mean age 45 years) were randomly assigned in a 2:1 ratio to receive PA 500 mg twice daily or matching placebo for 90 days. The primary outcome was the change in serum neurofilament light chain (sNfL) concentration, a biomarker of neuroaxonal damage, adjusted for age, body mass index, creatinine, and baseline sNfL.
Secondary outcomes included physical and cognitive performance measures and patient-reported outcomes, including fatigue and quality of life scores.
sNfL levels were significantly reduced in the PA group {−17.9%; from 9.77 pg/ml [95% confidence interval (CI) 9.00 to 10.60] to 8.02 pg/ml (95% CI 7.36 to 8.73); mean difference 1.75 pg/ml (95% CI 0.9 to 2.6); P = 0.000025}, while no significant change was observed in the placebo group. The adjusted mean difference in sNfL levels between the PA and placebo groups at follow-up was 0.91 pg/ml (95% CI 0.02 to 1.79; P = 0.045). Reductions in sNfL were also observed among participants in the PA arm receiving moderate-to-high efficacy disease-modifying therapies (n = 41; P = 0.0001), including those on anti-CD20 treatment (n = 27; P = 0.0005).
There was a trend towards improvement in motor fatigue in the PA group. No serious adverse events related to the study medication occurred.
PA supplementation was well tolerated and associated with significant reductions in sNfL, suggesting attenuation of neuroaxonal injury in multiple sclerosis. These findings support further evaluation of PA as an add-on treatment in larger, long-term studies.
Moser et al. evaluated the efficacy and safety of propionic acid (PA) as an add-on therapy in adults with clinically stable multiple sclerosis. They found that PA supplementation was well-tolerated and was associated with significant reductions in serum neurofilament light chain levels and a trend toward improvement in fatigue.
See Sandgren et al. (https://doi.org/10.1093/brain/awag192) for a scientific commentary on this article.
Publication and source details
Original title: Propionic acid in multiple sclerosis: a phase 2b, double-blind, randomized placebo-controlled trial
Tobias Moser; Wolfgang Hitzl; Tiago Lerda-Casaccia; Michael Unterhofer; Rina Demjaha; Maria Martinez-Serrat; Michael Khalil; Andrea Harrer; Belinda Böhm; Peter Hofbauer; Janne Cadamuro; Ursula Huber-Schönauer; Eugen Trinka; Peter Wipfler
Brain · 2026
Correspondence to: Tobias Moser, MD, PhD, Department of Neurology, Christian Doppler University Hospital, Paracelsus Medical University and Center for Cognitive Neuroscience, Ignaz-Harrer-Straße 79, Salzburg 5020, Austria E-mail: t.moser@salk.at© The Author(s) 2026. Published by Oxford University Press on behalf of the Guarantors of Brain.2026https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. ZeinPharma ZeinPharma Germany GmbH10.13039/501100008833 64569Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T22:10:21.270868+00:00
DOI: 10.1093/brain/awag099 · PMC13337218